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Introduction
Fumaric acid ester derivatives, or fumarates, have immu-
nomodulating properties [1]. For over four decades fuma-
rates have been applied in the treatment of psoriasis with
proven efficacy and long-term safety [2,3]. More recently,
fumarates have been assessed in multiple sclerosis [4].
Given their favorable safety-profile, fumarates could be of
value in the treatment of other immune-mediated inflam-
matory diseases.
Aim
To assess the response of fumarates in lupus erythematosus.
Methods
Two case-reports of patients with lupus erythematosus
who were treated with fumarates. Treatment was carried
out with enteric-coated tablets containing 120 mg
dimethylfumarate and 95 mg monoethylfumarate-salts.
The dosage was gradually increased up to 6 tablets
daily. Patients were followed up regularly with clinical
evaluations, laboratory tests, and urine analysis.
Results
A 35-year old female patient presented with an erythe-
matous indurated swelling of the nose that was present
for 1 year. Histology of a skin biopsy was consistent
with the diagnosis lupus timidus. Treatments included
hydroxychloroquine 200 mg two times a day for four
months and intralesional corticosteroid injections, but
both treatments were without effect. Therefore, fuma-
rates treatment was started. After 3 months the skin
lesions resolved completely. At one year follow-up the
clinical situation was stable with 4 tablets daily. Adverse
events were nausea, diarrhea, and mild leukopenia and
proteinuria, but these resolved gradually.
A 24-year old female patient presented with erythema-
tous scaly plaques, Raynaud’s phenomenon, alopecia, and
oral ulcera with positive antinuclear antibodies. She was
diagnosed with systemic lupus erythematosus. Treatments
with prednison, hydroxychloroquine, and cyclosporin were
ineffective. Therefore, fumarates in combination with pre-
dnisone 10 mg was started, which resulted in improve-
ment of the skin lesions. Because of a pregnancy wish,
fumarates was stopped. Re-treatment with fumarates had
an equally good effect within 3 months. Adverse events
included tiredness, pruritus, abdominal cramps, and tran-
sient proteinuria.
Conclusions
Fumarates seem beneficial in the treatment of lupus
erythematosus not responding to conventional systemic
treatments. The short-term side effect profile is similar to
that in psoriasis patients.
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